Vaccinating Against Colon Cancer Recurrences

Roy, H. K.; Thompson, Jon S.
June 1999
American Journal of Gastroenterology;Jun1999, Vol. 94 Issue 6, p1445
Academic Journal
Discusses research being done on the active specific immunotherapy for stage II and stage III human colon cancer. Reference to a study by J.B. Vermorken, A.M.E. Claessen, H. van Tinteren et al published in the 1999 issue of "Lancet"; Comparison between the effect of adjuvant chemotherapy on stage II and stage III colorectal cancer; Impact of bacille Calmette-Guérin vaccination on stage II and stage III colorectal cancer patients.


Related Articles

  • Immunotherapy: DNA vaccination during TB treatment generates super-protective immunity. Lowrie, Douglas B. // Gene Therapy;Apr2005, Vol. 12 Issue 7, p557 

    Discusses the study regarding the effectiveness of DNA vaccination in generating immunity during tuberculosis chemotherapy treatment. Concern over the insufficient immune response of individuals against mycobacterium tuberculosis; Suggestion to shorten chemotherapy treatment through...

  • Effective management of superficial bladder cancer. Lamm, Donald L. // Contemporary Urology;Feb2005 Supplement, Vol. 17, p1 

    Presents information on the use of the bacillus Calmette-Guérin (BCG) vaccine for the treatment of bladder cancer and carcinoma in situ. History of BCG immunotherapy; Comparison of the effectiveness of BCG with intravesical chemotherapy; Findings of a study of patients with bladder tumors...

  • Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. Yau-tong You; Chung-Rong Changchien; Jen-Seng Huang; Koon-Kwan Ng // International Journal of Colorectal Disease;Jan2006, Vol. 21 Issue 1, p33 

    Treatment of liver metastases from colorectal cancer include surgical resection, radiation, hepatic chemoembolization, immunotherapy and intravenous chemotherapy. Complete surgical resection of liver metastases is feasible only for solitary or unilobar metastasis. Unresectable hepatic metastases...

  • The management of peritoneal surface malignancy of colorectal cancer origin. Tentes, A. A. K. // Techniques in Coloproctology;Nov2004 Supplement 1, Vol. 8, ps39 

    Colorectal carcinomas are predominantly spread malignancies. Peritoneal carcinomatosis frequently associates colorectal carcinomas. The tumour grade, the completeness of cytoreduction, the tumour volume, the presence of distant metastases, prior surgery score and the extent of peritoneal...

  • Schering AG: Bonefos offers bone metastasis hope.  // PharmaWatch: Cancer;October 2004, Vol. 3 Issue 10, p7 

    This article reports that the FDA has granted priority review status to Bonefos. Genentech and Roche, co-developers of Avastin, have published potentially damaging results from randomized studies of the drug in patients with colorectal cancer. It was stated that the risk of a serious arterial...

  • Evaluation of CEA in patients with known residual disease after resection of colonic cancer. Lawton, J. O.; Giles, G. R.; Cooper, E. H. // Journal of the Royal Society of Medicine;Jan1980, Vol. 73 Issue 1, p23 

    Serial carcinoembryonic antigen (CEA) levels were measured in 43 patients following incomplete excision of colorectal cancer. Twenty-seven patients received chemotherapy. In the majority the subsequent elevation of CEA could be related to clinical progression, but some patients receiving...

  • Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. Jankova, Lucy; Robertson, Graham; Chan, Charles; Tan, King L.; Kohonen-Corish, Maija; Fung, Caroline; Clarke, Candice; Lin, Betty P. C.; Molloy, Mark; Chapuis, Pierre H.; Bokey, Les; Dent, Owen F.; Clarke, Stephen J. // BMC Cancer;2012, Vol. 12 Issue 1, p196 

    Background: This study examined the association between overall survival and Glutathione S-transferase Pi (GST Pi) expression and genetic polymorphism in stage C colon cancer patients after resection alone versus resection plus 5-fluourouracil-based adjuvant chemotherapy. Methods: Patients were...

  • GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Kweekel, D M; Koopman, M; Antonini, N F; Van der Straaten, T; Nortier, J W R; Gelderblom, H; Punt, C J A; Guchelaar, H-J // British Journal of Cancer;10/21/2008, Vol. 99 Issue 8, p1316 

    A Valine residue at position 105 of the GSTP1 protein results in decreased enzyme activity. As nuclear GSTP1 activity decreases irinotecan cytotoxicity, Val-allele carriers may benefit more from irinotecan chemotherapy. Our aim was to investigate the association of GSTP1 genotype with treatment...

  • Modulation of monocyte-tumour cell interactions byMycobacterium vaccae. Baran, Jaroslaw; Baj-Krzyworzeka, Monika; Weglarczyk, Kazimierz; Ruggiero, Irena; Zembala, Marek // Cancer Immunology, Immunotherapy;Dec2004, Vol. 53 Issue 12, p1127 

    Immunotherapy withMycobacterium vaccaeas an adjuvant to chemotherapy has recently been applied to treatment of patients with cancer. One of the mechanisms of antitumour activity ofMycobacterium bovisbacillus Calmette-Guérin (BCG), the prototype immunomodulator, is associated with activation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics